These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 9814956)

  • 1. Development of bivalent rgp120 vaccines to prevent HIV type 1 infection.
    Berman PW
    AIDS Res Hum Retroviruses; 1998 Oct; 14 Suppl 3():S277-89. PubMed ID: 9814956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses.
    Kumar A; Lifson JD; Silverstein PS; Jia F; Sheffer D; Li Z; Narayan O
    Virology; 2000 Aug; 274(1):149-64. PubMed ID: 10936096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand.
    Berman PW; Huang W; Riddle L; Gray AM; Wrin T; Vennari J; Johnson A; Klaussen M; Prashad H; Köhne C; deWit C; Gregory TJ
    Virology; 1999 Dec; 265(1):1-9. PubMed ID: 10603312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viral evolution in macaques coinfected with CCR5- and CXCR4-tropic SHIVs in the presence or absence of vaccine-elicited anti-CCR5 SHIV neutralizing antibodies.
    Burke B; Derby NR; Kraft Z; Saunders CJ; Dai C; Llewellyn N; Zharkikh I; Vojtech L; Zhu T; Srivastava IK; Barnett SW; Stamatatos L
    Virology; 2006 Nov; 355(2):138-51. PubMed ID: 16920175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults.
    Pitisuttithum P; Nitayaphan S; Thongcharoen P; Khamboonruang C; Kim J; de Souza M; Chuenchitra T; Garner RP; Thapinta D; Polonis V; Ratto-Kim S; Chanbancherd P; Chiu J; Birx DL; Duliege AM; McNeil JG; Brown AE;
    J Infect Dis; 2003 Jul; 188(2):219-27. PubMed ID: 12854076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of gp120-specific protective immune responses by genetic vaccination with linear polyethylenimine-plasmid complex.
    Garzón MR; Berraondo P; Crettaz J; Ochoa L; Vera M; Lasarte JJ; Vales A; Van Rooijen N; Ruiz J; Prieto J; Zulueta J; González-Aseguinolaza G
    Vaccine; 2005 Feb; 23(11):1384-92. PubMed ID: 15661387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission.
    Derdeyn CA; Decker JM; Bibollet-Ruche F; Mokili JL; Muldoon M; Denham SA; Heil ML; Kasolo F; Musonda R; Hahn BH; Shaw GM; Korber BT; Allen S; Hunter E
    Science; 2004 Mar; 303(5666):2019-22. PubMed ID: 15044802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a synthetic vaccine construct as antigen for the detection of HIV-induced humoral responses.
    Hewer R; Meyer D
    Vaccine; 2005 Mar; 23(17-18):2164-7. PubMed ID: 15755588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers.
    Belshe RB; Stevens C; Gorse GJ; Buchbinder S; Weinhold K; Sheppard H; Stablein D; Self S; McNamara J; Frey S; Flores J; Excler JL; Klein M; Habib RE; Duliege AM; Harro C; Corey L; Keefer M; Mulligan M; Wright P; Celum C; Judson F; Mayer K; McKirnan D; Marmor M; Woody G;
    J Infect Dis; 2001 May; 183(9):1343-52. PubMed ID: 11294665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polygene DNA vaccine induces a high level of protective effect against HIV-vaccinia virus challenge in mice.
    Shinoda K; Xin KQ; Jounai N; Kojima Y; Tamura Y; Okada E; Kawamoto S; Okuda K; Klinman D; Okuda K
    Vaccine; 2004 Sep; 22(27-28):3676-90. PubMed ID: 15315847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1.
    Berman PW; Murthy KK; Wrin T; Vennari JC; Cobb EK; Eastman DJ; Champe M; Nakamura GR; Davison D; Powell MF; Bussiere J; Francis DP; Matthews T; Gregory TJ; Obijeski JF
    J Infect Dis; 1996 Jan; 173(1):52-9. PubMed ID: 8537682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
    Gómez CE; Abaitua F; Rodríguez D; Esteban M
    Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proliferative responses to human immunodeficiency virus type 1 (HIV-1) gp120 peptides in HIV-1-infected individuals immunized with HIV-1 rgp120 or rgp160 compared with nonimmunized and uninfected controls.
    Sitz KV; Ratto-Kim S; Hodgkins AS; Robb ML; Birx DL
    J Infect Dis; 1999 Apr; 179(4):817-24. PubMed ID: 10068576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides.
    Jiang JQ; Patrick A; Moss RB; Rosenthal KL
    J Virol; 2005 Jan; 79(1):393-400. PubMed ID: 15596832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.
    Pitisuttithum P; Gilbert P; Gurwith M; Heyward W; Martin M; van Griensven F; Hu D; Tappero JW; Choopanya K;
    J Infect Dis; 2006 Dec; 194(12):1661-71. PubMed ID: 17109337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4.
    Pugach P; Kuhmann SE; Taylor J; Marozsan AJ; Snyder A; Ketas T; Wolinsky SM; Korber BT; Moore JP
    Virology; 2004 Mar; 321(1):8-22. PubMed ID: 15033560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccines against HIV.
    Carmichael AJ; Sissons JG
    QJM; 1995 Feb; 88(2):77-9. PubMed ID: 7704566
    [No Abstract]   [Full Text] [Related]  

  • 19. An HIV vaccine--evolving concepts.
    Johnston MI; Fauci AS
    N Engl J Med; 2007 May; 356(20):2073-81. PubMed ID: 17507706
    [No Abstract]   [Full Text] [Related]  

  • 20. DNA vaccines for immunodeficiency viruses.
    Robinson HL
    AIDS; 1997; 11 Suppl A():S109-19. PubMed ID: 9451974
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.